Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Optimal Antiplatelet Treatment to Achieve Stroke Avoidance and Fall in (post-LAA occlusion in ESRD on dialysis)
2021-006127-17Phase 4Active
- Sponsor
- National Institute of Cardiology
- Start
- Mar 2022
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of clopidogrel and aspirin in Atrial fibrillation (AFib), end-stage kidney disease (ESKD) and chronic kidney disease (CKD), sponsored by National Institute of Cardiology. Primary endpoint: Composite primary endpoint. Started Mar 2022; status: active.
02
Drugs
clopidogrelaspirin
03
Conditions
Atrial fibrillation (AFib)end-stage kidney disease (ESKD)chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-006127-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-006127-17.